Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '19 Jan '20 Dec '20 Jan '21 Dec '21 Jan '22 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
5,710.53 — 6,099.93 — 5,836.37 — 6,389.00 7,134.50 7,804.52 8,512.65
Revenue Growth
7.77% 5.07% 6.82% (0.16%) (4.32%) 18.07% 9.47% 11.67% 9.39% 9.07%
Cost of Revenue
3,088.35 — 3,523.85 — 3,514.43 — 4,037.86 4,434.62 4,780.55 5,277.98
Gross Profit
2,622.18 — 2,576.08 — 2,321.95 — 2,351.14 2,699.87 3,023.97 3,234.67
R&D Expenses
309.14 — 336.08 — 419.86 — 380.50 427.81 415.57 481.98
SG&A Expenses
1,055.96 — 1,125.87 — 1,255.87 — 1,254.23 1,479.15 1,358.35 1,338.45
Operating Income
1,267.13 — 1,137.88 — 704.02 — 848.86 865.19 1,289.88 1,406.33
Non-operating Income/Expense
(351.97) — (134.22) — (289.40) — (468.24) (622.73) (809.43) (710.52)
Non-operating Interest Expenses
384.12 — 285.16 — 328.89 — 523.14 645.99 773.45 707.13
EBT
915.16 — 1,003.66 — 414.62 — 380.62 242.45 480.45 695.81
Income Tax Provision
188.67 — 193.78 — 100.71 — 94.94 46.92 250.17 130.11
Income after Tax
726.48 — 809.88 — 313.91 — 285.68 195.54 230.28 565.70
Dividends (Preferred)
— — 0.00 — 0.00 — — — — —
Non-Controlling Interest
26.32 — 103.31 — 90.63 — 66.24 131.34 60.47 110.88
Net Income Common
700.16 — 706.57 — 223.28 — 219.44 64.20 169.80 454.82
EPS (Basic)
1.02 — 1.03 — 0.32 — 0.33 0.10 0.25 0.67
EPS (Diluted)
1.02 — 1.03 — 0.32 — 0.33 0.10 0.25 0.67
Shares (Basic, Weighted)
685.12 — 685.52 — 681.56 — 679.81 679.76 679.67 680.51
Shares (Diluted, Weighted)
684.72 — 685.14 — 681.40 — 679.29 677.10 679.67 681.57
Gross Margin
45.92% 39.93% 42.23% 36.79% 39.78% 34.61% 36.80% 37.84% 38.75% 38.00%
EBIT Margin
22.19% 36.52% 18.65% 22.91% 12.06% 22.63% 13.29% 12.13% 16.53% 16.52%
EBT margin
16.03% 14.94% 16.45% 5.78% 7.10% 4.27% 5.96% 3.40% 6.16% 8.17%
Net Profit Margin
12.26% 11.59% 11.58% 3.83% 3.83% 3.43% 3.43% 0.90% 2.18% 5.34%
Free Cash Flow Margin
3.13% 20.97% 14.01% 12.33% 10.74% 0.00% (6.32%) (1.24%) 7.69% 8.35%
EBITDA
1,605.88 — 1,505.17 — 1,129.66 — 1,278.59 1,343.48 1,763.73 1,915.46
EBIT
1,267.13 — 1,137.88 — 704.02 — 848.86 865.19 1,289.88 1,406.33
Income from Continuous Operations
726.48 — 809.88 — 313.91 — 285.68 195.54 230.28 565.70
Consolidated Net Income/Loss
726.48 — 809.88 — 313.91 — 285.68 195.54 230.28 565.70
EPS (Basic, from Continuous Ops)
1.06 — 1.18 — 0.46 — 0.42 0.29 0.34 0.83
EPS (Basic, Consolidated)
1.06 — 1.18 — 0.46 — 0.42 0.29 0.34 0.83
EPS (Diluted, from Cont. Ops)
1.06 — 1.18 — 0.46 — 0.42 0.29 0.34 0.83
Shares (Diluted, Average)
686.97 — 685.52 — 677.05 — 679.29 679.76 679.92 681.57
EPS (Diluted, Consolidated)
1.06 — 1.18 — 0.46 — 0.42 0.29 0.34 0.83
EBITDA Margin
28.12% 24.29% 24.68% 18.59% 19.36% 18.04% 20.01% 18.83% 22.60% 22.50%
Operating Cash Flow Margin
11.16% 20.97% 20.79% 12.33% 12.10% 0.00% (0.18%) 3.16% 12.51% 13.92%

Fold the line items

In millions of $ except per-share values · columns are period end dates